Literature DB >> 33231544

Clinical Guideline Highlights for the Hospitalist: Therapeutic Monitoring of Vancomycin.

Mark Murphy1,2, Sonya Tang Girdwood2,3,4, Marc H Scheetz5,6,7.   

Abstract

GUIDELINE TITLE: Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists RELEASE DATE: Online: March 19, 2020 PRIOR VERSION: 2009 DEVELOPERS: American Society of Health-System Pharmacists (ASHP), the Infectious Diseases Society of America (IDSA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP) FUNDING SOURCE: ASHP, IDSA, PIDS, SIDP TARGET POPULATION: Adults, children, and neonates treated for documented or presumed methicillin-resistant Staphylococcus aureus infection.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33231544      PMCID： PMC8034673          DOI： 10.12788/jhm.3507

Source DB:  PubMed          Journal:  J Hosp Med        ISSN： 1553-5592            Impact factor:   2.960


  11 in total

1.  The periodic health examination. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  Can Med Assoc J       Date:  1979-11-03       Impact factor: 8.262

Review 2.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Am J Health Syst Pharm       Date:  2009-01-01       Impact factor: 2.637

3.  Vancomycin monitoring in children using bayesian estimation.

Authors:  Jennifer Le; Becky Ngu; John S Bradley; William Murray; Austin Nguyen; Lyn Nguyen; Gale L Romanowski; Tiana Vo; Edmund V Capparelli
Journal:  Ther Drug Monit       Date:  2014-08       Impact factor: 3.681

4.  Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing.

Authors:  Michael N Neely; Lauren Kato; Gilmer Youn; Lironn Kraler; David Bayard; Michael van Guilder; Alan Schumitzky; Walter Yamada; Brenda Jones; Emi Minejima
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

5.  Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael J Rybak; Jennifer Le; Thomas P Lodise; Donald P Levine; John S Bradley; Catherine Liu; Bruce A Mueller; Manjunath P Pai; Annie Wong-Beringer; John C Rotschafer; Keith A Rodvold; Holly D Maples; Benjamin M Lomaestro
Journal:  Am J Health Syst Pharm       Date:  2020-05-19       Impact factor: 2.637

6.  Evaluation of Target Attainment of Vancomycin Area Under the Curve in Children With Methicillin-Resistant Staphylococcus Aureus Bacteremia.

Authors:  Andrea Hahn; Robert W Frenck; Mary Allen-Staat; Yuanshu Zou; Alexander A Vinks
Journal:  Ther Drug Monit       Date:  2015-10       Impact factor: 3.681

7.  Nephrotoxicity With Vancomycin in the Pediatric Population: A Systematic Review and Meta-Analysis.

Authors:  Theresa M Fiorito; Megan K Luther; Penelope H Dennehy; Kerry L LaPlante; Kelly L Matson
Journal:  Pediatr Infect Dis J       Date:  2018-07       Impact factor: 2.129

8.  Healthcare-associated Staphylococcus aureus Bacteremia in Children: Evidence for Reverse Vancomycin Creep and Impact of Vancomycin Trough Values on Outcome.

Authors:  J Chase McNeil; Eric Y Kok; Andrea R Forbes; Linda Lamberth; Kristina G Hulten; Jesus G Vallejo; Edward O Mason; Sheldon L Kaplan
Journal:  Pediatr Infect Dis J       Date:  2016-03       Impact factor: 2.129

9.  Pharmacodynamic Characteristics of Nephrotoxicity Associated With Vancomycin Use in Children.

Authors:  Jennifer Le; Pamela Ny; Edmund Capparelli; James Lane; Becky Ngu; Richard Muus; Gale Romanowski; Tiana Vo; John Bradley
Journal:  J Pediatric Infect Dis Soc       Date:  2014-11-03       Impact factor: 3.164

Review 10.  Association between the AUC0-24/MIC Ratio of Vancomycin and Its Clinical Effectiveness: A Systematic Review and Meta-Analysis.

Authors:  Peng Men; Hui-Bo Li; Suo-Di Zhai; Rong-Sheng Zhao
Journal:  PLoS One       Date:  2016-01-05       Impact factor: 3.240
View more
  1 in total

1.  Population pharmacokinetic model of vancomycin in postoperative neurosurgical patients.

Authors:  Shifeng Wei; Dongjie Zhang; Zhigang Zhao; Shenghui Mei
Journal:  Front Pharmacol       Date:  2022-09-26       Impact factor: 5.988
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.